FDA: Diabetes patients using fluoroquinolones for infections face risks

08/28/2013 | AAFP News Now

The FDA told physicians that prescribing fluoroquinolones to treat bacterial infections in patients with diabetes poses a serious health risk and said it is requiring label and medication guide changes due to the possibility of permanent nerve damage. A study in the journal Clinical Infectious Diseases showed diabetes patients on fluoroquinolones had a higher risk of severe dysglycemia compared with those taking macrolides or cephalosporins, and that moxifloxacin appeared to have the greatest risk.

View Full Article in:

AAFP News Now

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC